What are the benefits of early initiation of anticoagulation (Anti-Coagulant) therapy in patients with ischemic stroke?

From the Guidelines

Early initiation of anticoagulation therapy in patients with ischemic stroke is recommended, but the timing depends on individual risk assessment and stroke characteristics, with most guidelines suggesting initiation between 4-14 days after stroke onset. When considering the benefits of early anticoagulation in patients with ischemic stroke, it's crucial to weigh the risks of recurrent ischemic stroke against the risks of hemorrhagic transformation and intracranial bleeding. According to a recent observational study 1, early anticoagulation at 4 to 14 days after cardioembolic stroke had the best outcome, but the study lacked statistical power to determine the benefit of earlier anticoagulation.

Key Considerations

• The size of the cerebral infarct is associated with an increased risk of both symptomatic hemorrhagic transformation and early recurrent ischemia 1.
• A systematic review and meta-analysis of 7 randomized trials found that early anticoagulation was associated with nonsignificantly reduced recurrent ischemic stroke but with increased intracranial bleeding, and no reduction in death or disability 1.
• Observational data suggest that the use of low molecular weight heparin (LMWH) together with oral anticoagulation is associated with a higher risk of symptomatic hemorrhage 1.
• Some studies suggest that early (< 14 days) anticoagulation with non-vitamin K antagonist oral anticoagulants (NOACs) might be safe, with improved outcomes and no early intracranial hemorrhage 1.

Recommendations

• For most patients with ischemic stroke, anticoagulants should be avoided in the first 24-48 hours after stroke onset, and aspirin should be started within 24-48 hours 1.
• The decision to initiate anticoagulation should be based on individual risk assessment, taking into account the size and severity of the stroke, as well as the patient's bleeding risk.
• Before initiating anticoagulation, a follow-up brain imaging should be performed to rule out hemorrhagic transformation 1.

Anticoagulation Timing

• The optimal timing of anticoagulation initiation is not well established, but most guidelines suggest starting between 4-14 days after stroke onset, depending on stroke size and individual bleeding risk 1.
• Some studies suggest that early initiation of anticoagulation, even within 4-5 days, might be safe and effective in certain patients, such as those with atrial fibrillation 1.

From the FDA Drug Label

Apixaban treatment resulted in a significantly lower rate of all-cause death (p = 0. 046) than did treatment with warfarin, primarily because of a reduction in cardiovascular death, particularly stroke deaths.

The benefits of early initiation of anticoagulation therapy in patients with ischemic stroke include:

• Reduced risk of stroke deaths: Apixaban treatment resulted in a significantly lower rate of all-cause death, primarily due to a reduction in cardiovascular death, particularly stroke deaths.
• Lower rate of all-cause death: Apixaban treatment was associated with a significantly lower rate of all-cause death compared to warfarin.

2

From the Research

Benefits of Early Initiation of Anticoagulation Therapy

The benefits of early initiation of anticoagulation therapy in patients with ischemic stroke include:

• Reduced risk of recurrent ischemic stroke 3, 4, 5
• Lower risk of intracranial hemorrhage with direct oral anticoagulants compared to older anticoagulants 3, 4
• Potential prevention of recurrence and reduction of stroke risk 3, 5
• Similar or better efficacy of early treatment with direct oral anticoagulants compared to delayed initiation 3, 5

Outcomes of Early Anticoagulation

Studies have reported the following outcomes of early anticoagulation:

• Statistically similar yet generally numerically lower rates of recurrent strokes/TIA, death, fatal strokes, and symptomatic hemorrhages with early apixaban use compared to warfarin 5
• No symptomatic intracerebral hemorrhage occurred with apixaban, while one occurred with warfarin 5
• Early initiation of anticoagulation after TIA, small-, or medium-sized AIS from AF does not appear to compromise patient safety 5
• Reduced composite risk of major bleeding, thrombotic events, and all-cause mortality with early anticoagulation compared to late anticoagulation in non-AF indications 6

Timing of Anticoagulation

The optimal timing of anticoagulation after acute ischemic stroke is still an area of clinical equipoise, with studies suggesting:

• Early anticoagulation may be safe and effective in patients with mild-to-moderate AIS and AF 7
• Delayed anticoagulation may be considered in patients with severe AIS to avoid serious bleeding events 7
• A "1-3-6-12 days" rule to resume OACs after AIS may not be suitable for all patients, and individualized decision-making is necessary 7